
ATL Announces New VP of Human Resources
November 2, 2023
Springville, Utah, October 27, 2023—ATL Technology, a dynamic and rapidly expanding company specializing in medical device development and manufacturing, is thrilled to introduce Danelle Goulet as the new Vice President of Human Resources.
Expressing her enthusiasm for her new role, Danelle shared, “I am excited by the challenge of a fast-growing company in the medical device space. The company’s commitment to its customers, investors, and employees is impressive, but ultimately, we are all here for the patients that will benefit from the medical device innovations that ATL drives. That is something very special to be a part of at this time.”
Before joining the ATL Technology family, Danelle served as the Vice President of HR & Facilities for Advanced Input Systems. Danelle also held leadership roles at IBM and Amgen.
ATL Technology CEO, Joe Glover, said. “Danelle’s experience is well aligned to ATL’s growth trajectory, and I am confident that she will be a great addition to our leadership team and help us continue to grow in a way that benefits all stakeholders.”
About ATL Technology: Founded in 1993, ATL is a fast-growing medical device company offering design, development, and manufacturing services. The company focuses on providing its customers with world-class engineering solutions to help them accelerate medical device innovation.
For media inquiries or more information, please contact:
Dianna Fox, Sr. Global Marketing Director
Tel +1 224.430.4690
Email: Dianna.fox@atltechnology.com
www.atltechnology.com
Recent News
- Collaboration with Quest Diagnostics to expand kidneyintelX.dkd TM testing in the United States
- Utah Business Innovation Awards Summit Recap
- Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
- Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
- Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome















